As doubts con­tin­ue to fes­ter, In­ovio gets an­oth­er shove as Roche ex­its col­lab­o­ra­tion

Three years af­ter Roche signed up for a $422 mil­lion col­lab­o­ra­tion pact with In­ovio $INO on a pair of its ear­ly-stage de­vel­op­ment pro­grams, the phar­ma gi­ant is bow­ing out of the last re­main­ing ef­fort in the part­ner­ship. In­ovio says that it will take over the Phase I study for the he­pati­tis B vac­cine INO-1800, which is now fi­nal­ly en­rolling pa­tients.

Roche took con­sid­er­ably less time on INO-5150, its can­cer vac­cine. The com­pa­ny bowed out of that pro­gram in 2014. At the time, In­ovio had said it was start­ing a Phase I on 5150 in 2015. But ac­cord­ing to its pipeline chart, that’s where it still sits to­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER